IFNB1 and neoplasm: In well‐controlled syngeneic tumor models, single‐dose SNX281 induced remarkable complete regression in 60% of treated mice, correlating with dramatic 100‐fold increases in tumor IFN‐β levels versus cyclic dinucleotide controls, demonstrating exceptional immunomodulatory activity and therapeutic efficacy.